and a far greater number of patients.
FWIW the reason I put back to Chiasma is really outside of the success or failure or even anything to do with the actual drug it was more about the structure of the deal. Comparatively if ANP is searching for a deal where the party covers the Phase III trial then right there that is say $30M so they are contributing greater than the company is worth at this point just to put the drug through --- what would they want for that ? As obviously ANP doesn't have the funds to do it without another party stepping in. Chiasma got a big figure upfront basically because it reimbursed the already funded phase III the bulk of the deal as with milestones was set at the back end of product in market.
My bet is if a partner steps in to fund the Phase III trial they will take a big equity stake with it.
Just me view,
- Forums
- ASX - By Stock
- Ann: Strategy Update - ATL1103 & ATL1102
and a far greater number of patients. FWIW the reason I put back...
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
8.2¢ |
Change
-0.003(3.53%) |
Mkt cap ! $85.01M |
Open | High | Low | Value | Volume |
8.5¢ | 8.6¢ | 8.2¢ | $103.7K | 1.237M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 204084 | 8.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.5¢ | 280000 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 204084 | 0.082 |
3 | 287000 | 0.081 |
8 | 672686 | 0.080 |
6 | 413817 | 0.079 |
6 | 689399 | 0.078 |
Price($) | Vol. | No. |
---|---|---|
0.085 | 280000 | 3 |
0.086 | 96543 | 1 |
0.088 | 27962 | 1 |
0.089 | 200000 | 1 |
0.090 | 604764 | 4 |
Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online